Bullish option flow detected in Crispr Therapeutics with 9,064 calls trading, 2x expected, and implied vol increasing almost 4 points to 77.30%. Dec-23 55 calls and Jan-24 60 calls are the most active options, with total volume in those strikes near 2,100 contracts. The Put/Call Ratio is 0.28. Earnings are expected on February 20th.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRSP:
- Crispr Therapeutics price target lowered to $50 from $55 at RBC Capital
- Crispr Therapeutics price target lowered to $85 from $88 at Needham
- Crispr Therapeutics price target lowered to $56 from $64 at Barclays
- Crispr Therapeutics reports Q3 EPS ($1.41), consensus ($1.95)
- CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results